Physician profile
Jill Mcclory
NPI 1922190255
$8,642.10
in general payments reported to CMS, 2019-2025
33 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $398 · 2021: $369 · 2022: $1,299 · 2023: $1,852 · 2024: $1,848 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,019 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,018.87 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,662.56 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,060.07 | 2019-2025 | |
| Ucb, INC. | $898.81 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $872.58 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $535.81 | 2019-2025 | |
| Pfizer INC. | $501.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $386.00 | 2019-2023 | Orencia |
| Astrazeneca Pharmaceuticals LP | $312.62 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $301.22 | 2019-2024 | Taltz |
| Genzyme Corporation | $199.81 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $199.53 | 2019-2025 | Strensiq |
| Glaxosmithkline, LLC. | $184.76 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $176.85 | 2019-2023 | Krystexxa |
| Organon LLC | $171.29 | 2022-2025 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $134.14 | 2023-2025 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $122.64 | 2019-2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $117.86 | 2020-2024 | Acthar |
| Radius Health, INC. | $106.69 | 2020-2025 | Tymlos |
| Sandoz INC. | $104.97 | 2023-2025 | Hyrimoz, Jubbonti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.66 | 2023-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $91.39 | 2022-2023 | Purified Cortrophin Gel |
| Sobi, INC | $68.99 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $56.60 | 2024 | Uptravi, Opsumit |
| Scilex Pharmaceuticals INC. | $49.02 | 2024 | |
| Mallinckrodt Enterprises LLC | $44.08 | 2019 | |
| Celgene Corporation | $31.97 | 2019 | |
| Antares Pharma, INC. | $31.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.15 | 2019 | |
| Merck Sharp & Dohme LLC | $26.11 | 2019-2021 | |
| Octapharma USA, INC. | $22.52 | 2022 | |
| Pacira Therapeutics, INC. | $18.63 | 2020 | |
| Assertio Therapeutics, INC. | $14.40 | 2019 | |
| Hikma Pharmaceuticals USA | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mcclory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.